Alzinova AB (publ) announced the company has successfully completed the humanisation work and selected a humanised lead candidate of its monoclonal antibody ALZ-201. Alzinova initiated work to humanise the monoclonal antibody ALZ-201 in the second quarter of 2021. The company has now successfully completed the humanisation activities and selected the lead candidate, which will be further developed with the aim to strengthen Alzinova's portfolio of disease modifying therapies and to offer an additional treatment approach to help patients suffering from Alzheimer's disease.

Several back-up candidates with promising profiles have also been developed. Unique specificity and preclinical efficacy: In December 2021, Alzinova communicated the results from a research collaboration with Amsterdam University Medical Centers. Data from the project confirmed the unique specificity and preclinical efficacy of ALZ-201.

The humanised monoclonal antibody, ALZ-201, has the potential to be developed as a novel therapy to specifically target toxic forms of the amyloid beta peptide (oligomers), and thus prevent its neurotoxic effect on neurons. Aggregation of the amyloid beta in the brain is widely recognized as a main driver of Alzheimer's disease. Both ALZ-201 and the related therapeutic vaccine, ALZ-101, which is in clinical development, are novel immunotherapies with very specific and targeted effects, which could translate to more favorable clinical profiles with best-in-class potential compared to other amyloid beta-targeting immunotherapies.

The company plans to communicate more details on the future development of ALZ-201 during the first half of 2022.